Tetraphase Bets On I.V. Eravacycline Rerun As Antibiotic Market Influx Looms

 
• By Lucie Ellis-Taitt

Tetraphase has been keeping its head down since a 2015 Phase III trial failure for its lead antibiotic drug eravacycline sliced around $1.3bn from the company's market cap – but 2017 will be a turnaround year, says CEO Guy Macdonald.

Guy Macdonald
Tetraphase CEO Guy Macdonald Has High Hopes For Lead Antibiotic Despite Past Failure • Source: Tetraphase Pharmaceuticals

More from Anti-infective

More from Therapy Areas